IDEXX Laboratories Inc (IDXX)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $55.48B
Last updated: Nov 17, 2026 at 11:06 AM ET
IDEXX Laboratories Inc (IDXX) Stock Forecast
Analysts expect IDEXX Laboratories (IDXX) to earn $15.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.76B. Of 14 analysts, 9 rate the stock Buy or Strong Buy, 4 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 2.21, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 64% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 28.6% |
| Buy | 5 | 35.7% |
| Hold | 4 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 1 | 7.1% |
- Consensus
- Buy
- Total analysts
- 14
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 12.5% and revenue estimates rise 8.8%.
- Fiscal year ending Dec 31, 2026
- $15.02
- EPS consensus, revenue $4.76B
- Fiscal year ending Dec 31, 2027
- $16.89
- EPS consensus, revenue $5.18B
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $15.02 | $14.65 to $15.13 | 11 | $4.76B | $4.75B to $4.77B | 13 |
| Dec 31, 2027 | $16.89 | $16.59 to $17.15 | 13 | $5.18B | $5.10B to $5.28B | 13 |
Quarterly Estimates
The EPS consensus rises from $3.38 for the quarter ending Dec 31, 2026 to $3.96 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.38 | $3.19 to $3.57 | 15 | $1.21B | $1.16B to $1.25B | 13 |
| Mar 31, 2027 | $3.96 | $3.88 to $4.03 | 7 | $1.24B | $1.23B to $1.27B | 5 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 1.2% from $14.84.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $15.02 | $14.94 | $14.83 | $14.84 | $14.84 | +1.3% |
| Fiscal year ending Dec 31, 2027 | $16.89 | $16.82 | $16.74 | $16.74 | $16.74 | +0.9% |
| Quarter ending Mar 31, 2027 | $3.96 | $3.96 | $3.96 | $3.96 | $3.94 | +0.5% |
Frequently Asked Questions About IDXX
What is the IDXX stock forecast?
Consensus analyst estimates put IDEXX Laboratories's EPS at $15.02 for the fiscal year ending Dec 31, 2026, on revenue of $4.76B. The consensus rating from 14 analysts is Buy.
How do analysts rate IDXX stock?
Of 14 analysts covering IDEXX Laboratories, 4 rate it Strong Buy, 5 Buy, 4 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from IDXX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $15.02, with estimates from $14.65 to $15.13 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $16.89, with estimates from $16.59 to $17.15 from 13 analysts.
What revenue do analysts expect from IDEXX Laboratories next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.76B, with estimates from $4.75B to $4.77B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $5.18B, with estimates from $5.10B to $5.28B.
How many analysts cover IDXX?
14 analysts rate IDEXX Laboratories stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IDXX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts